scispace - formally typeset
Open AccessJournal Article

Long-term survival.

Cho Yw, +1 more
- 01 Jan 1988 - 
- pp 277
TLDR
In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year, and for patients receiving kidneys with no HLA-A,B mismatches, the average half- life was 10.1 years.
Abstract
1. In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year. Second cadaver donor grafts had a half-life of 5.1 to 6.5 years. Parental donor grafts had a half-life of 9.3 to 11.8 years, whereas HLA identical sibling donor transplants had a half-life of 19.1 to 26.5 years. Siblings with no haplotype in common had an average half-life of 8.7 years. 2. Between 1971 and 1984, white recipients had an average half-life of 7.7 years, which increased to 9.3 years in 1985-1986. Black recipients' half-life decreased from 5.4 years in 1975-1976 to 3.5 years in 1985-1986. The reason for this decrease is not apparent. 3. The half-life of transplants of different recipient ages did not vary significantly. The average half-life during this period of study was 7.4 years for those younger than 21 years of age, 8.2 years for recipients 21 to 50 and 6.7 years for those older than 50. 4. In the early data, there was some evidence that the half-life of kidneys with cold ischemia below 13 hours was superior. However, in the latest period (between 1983 and 1986) the average half-life was 7.6 years for CIT below 13 hours, 7.2 years for those with 13 to 24 hours and 6.4 years for more than 24 hours. 5. For patients receiving kidneys with no HLA-A,B mismatches, the average half-life was 10.1 years. Those with A,B mismatches had a half-life of 6.7 years, and for those with no A,B antigens in common, the average half-life was 6 years. 6. In the period after 1981, the average half-life of patients with no A,B,DR mismatches was 9.1 years compared with 6.5 years for those with A,B,DR mismatches and 5.4 years for those with no A,B,DR antigens in common.

read more

Citations
More filters
Journal ArticleDOI

Treatment Outcome and Prognostic Factors of Malignant Thymoma - A Single Institution Experience.

TL;DR: The findings of this study indicates that late Masaoka-Koga staging and histology types are significantly associated with extended overall survival and surgical resection and multimodality treatments play a significant role in thymic malignancies neoplasms therapy strategies to prolong survival rates.
Journal ArticleDOI

Immunology in the Clinic Review Series; focus on host responses: invariant natural killer T cell activation following transplantation.

TL;DR: This paper presents a meta-anatomy of the central nervous system and some of the mechanisms leading to anxiety, depression, and substance abuse that are known to occur after certain types of injuries.
Journal ArticleDOI

Role of amoebae for survival and recovery of ‘non-culturable’ Helicobacter pylori cells in aquatic environments

TL;DR: Evidence is provided to support the hypothesis that amoebae and perhaps other free-living protozoa contribute to the replication and persistence of human-pathogenic H. pylori by providing a protected intracellular microenvironment for this pathogen to persist in natural aquatic environments and engineered water systems.
Journal ArticleDOI

Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study

TL;DR: The results of this study indicate that a total radiation dose up to 55.0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m 2) in patients with resected pancreatic carcinoma.
Dissertation

Characterising the plasticity of cutaneous myeloid cells in graft-versus-host disease

TL;DR: Together, this work has demonstrated the plasticity of myeloid cells within the skin after disease and the potential long-term consequences for skin immunity in patients who have recovered from GVHD.
Related Papers (5)
Trending Questions (1)
What is the biological half-life of the kidneys?

The biological half-life of kidneys varies based on donor type, recipient race, age, cold ischemia time, and HLA mismatches, ranging from 5.4 to 26.5 years in different scenarios.